Background: ICD/BVP indications are expanding. They are expensive devices and historically, morbidities associated with their use were high. The starting experience at the Gold Coast Hospital is being reviewed. 
Introduction
ICDs are very effective in the secondary prevention of sudden cardiac death; their effectiveness over placebo and antiarrhythmic drugs has been demonstrated in major multicentre randomised controlled trials (6, 7, 8, and 9) . The indications for the implantation of ICDs have quickly expanded from the secondary prevention of sudden cardiac death in persons who suffered a VT/ VF cardiac arrest to be used more in the primary prevention of sudden cardiac death in persons at risk of arrhythmic cardiac death after their effectiveness was shown in big trials (6, 10, 11, 12, 13 ) the factor which had the largest impact on the increase in their use in recent years, the benefit is claimed to be a 20-30% relative reduction in mortality at one year, which is maintained over 3-5 years of follow-up, the absolute mortality benefit was approximately 1-3% per year compared to standard medical treatment (1). BVPs is another area of device therapy which is quickly developing; BVPs reduce symptoms and frequency of hospitalisation when carried out in patients with symptomatic dilated CHF and prolonged QRS duration. A recent study has also demonstrated a mortality benefit of BVPs in patients with heart failure (1, 13). We wanted to present our own registry in the first year of our institute's experience with ICD/BVPs implantation, looking mainly at the implantation indications and all complications that we could trace.
Methods
A list of all ICDs and BVPs was taken from the catheter laboratory at the Gold Coast Hospital from the start of the program with the first ICD implanted on 6 th July 2007 till the end of analysis period on the 17 th July 2008 which included a total of thirty one devices, charts were requested and reviewed. Excel tables were created with the patients' characteristics, device indications, device type by function, device manufacturer, device cost, procedure time, hospital stay, use of antibiotics, use of chest x-ray to check for device position and procedure complication, device check by manufacturer, documented immediate complications, follow up including all device related re-admissions, device check-up and all adjustments, referrals to another institute and their outcomes.
Results
A total of 31 devices in 31 patients were implanted (25 male, 6 female), Mean patient's age was 58 years (20-75 years), and mean follow-up period was 9 months (3-15 months). Primary prevention devices were 21 (67%), secondary prevention devices were 10 (33%), the commonest single indication in our series was nonischemic dilated cardiomyopathy (11 patients 35%), the second most common indication was out-of-hospital cardiac arrest which occurred in 8 patients (26%) while conscious VT was next (4 patients 13%), ischemic dilated cardiomyopathy 3 patients (10%), 2 patients (6%) had inhospital-cardiac arrest, 2 patients had congenital long QT syndrome (6%) and 1 patient had catecholamine-related polymorphic VT (3%), table (1) . For patient's characteristics, co-morbidities and medications refer to tables (2, 3, 4) 21 devices (70%) were single chamber ICDs with a single right ventricular sensing pacing and defibrillating lead, 4 devices (13%) were double chamber ICDs with an additional atrial sensing and pacing lead as well, 5 devices (16%) were BVPs with the addition of a coronary sinus lead to the double chamber ICD to pace the left ventricle to achieve cardiac resynchronization function and finally, one patient had an ICD pulse generator replaced only (because of battery run out).
Devices manufacturers were; St. Jude Medical 17 devices (55%), Medtronic 11 devices (35%) and Guidant 3 devices (10%).
All devices were implanted subcutaneously in the left pectoral area; all patients had prophylactic antibiotics intra-operatively with intra-venous Cephazolin plus intra-venous Gentamycin in selected patients. All patients had prophylactic oral antibiotics with Cephalexin for 5 days post-procedure. All patients in our series had a check chest X-ray the first post-procedure day, all devices were checked by manufacturer, all patients had device check at 6 weeks and then at 6 monthly intervals thereafter except one patient.
The majority of the devices were implanted in a day procedure, 18 (58%), 8 patients (26%) had a hospital stay from 2-7 days, of them 3 patients had a conscious VT within the same hospital admission and 5 patients (16%) had a hospital stay of more than 7 days all of them had a cardiac arrest within the same hospital admission and a prolonged intensive care unit stay prior to the implantation procedure. Procedure duration was properly documented in 25 patients (80%), in the majority it was less than 90 minutes (17 procedures 54%), only 4 (13%) procedures lasted longer than 180 minutes and they were all BVPs.
Twenty one patients (67%) in our series had reported some complications, ten had reported none, and around thirty complication occurrences were documented. These were procedure related or device related. Procedural complications were; significant pain requiring narcotic analgesics in six patients, significant bleeding from implantation wound which required local pressure in two patients plus intra-venous desmopressin infusion in one patient, local hematoma in one patient which happened on the 8 th post-procedure day secondary to minor trauma, minor haemoptysis on the 3 rd post-procedure day in one patient (CT scan of the chest confirmed lung contusion which was managed conservatively) and one patient was admitted with left sided haemothorax on the 14 th post-procedure day despite the fact that chest X-ray taken on the 1 st post-procedure day was normal, required two inter-costal chest drains and video-assisted thoracoscopic procedure to stop the bleeding, two patients failed coronary sinus lead positioning for BVP, one patient eventually had an epicardial lead placed on mini-thoracotomy at another hospital to achieve BV pacing, the other was changed to single chamber ICD mode and the atrial lead was retrieved at a later date because that patient developed atrial fibrillation and failed cardio-version, one patient developed left subclavian vein thrombosis on the 10 th post-procedure day, one patient developed persistent left shoulder and ICD pocket pain and was referred to another hospital to consider submuscular implantation of the ICD.
As far as the device complications are concerned, Inappropriate discharges occurred in four patients, in the first patient it was for a supraventricular tachycardia falling in the VT detection zone for that the ICD was reprogrammed, in the second patient it was for a nonsustained VT after anti-tachycardia pacing mode failure secondary to under-rate detection for which ICD was reprogrammed but inappropriate discharge recurred for a non-sustained VT as well which failed to respond to antitachycardia pacing therapy appropriately delivered by the device this patient was started on treatment with amiodarone to suppress the non-sustained VTs, in a third patient it was for an atrial flutter falling in the VT detection zone in whom a trial of radiofrequency catheter ablation of the atrial flutter was attempted but failed and both atrial flutter and inappropriate discharge of the ICD recurred, the patient was eventually referred to another hospital to attempt atrial flutter ablation with a thermocool catheter and 3D mapping, and in the last patient it was for over-sensing noise caused by ICD pocket manipulation, in this patient the right ventricular lead was unscrewed and re-inserted at the ICD pocket. One patient received an appropriate discharge which was for VF properly sensed and terminated. Other therapies administered were anti-tachycardia pacing which successfully terminated sustained VT in two patients.
Lead related complications occurred in five patients; coronary sinus lead needed to be repositioned in one patient because of diaphragmatic stimulation on the 22 nd post-implantation day, right ventricular lead had to be repositioned into right ventricular apex in one patient on the 5 th post-implantation day as was under-sensing, atrial lead had to be removed on the 10 th post-implantation day in one patient as it was not in place and the patient developed atrial fibrillation which persisted after a trial of electric cardio-version, right ventricular lead had to be repositioned in one patient because of high threshold on the 29 th post-implantation day and lastly one patient needed a special right ventricular lead to replace the original lead which was done in a different hospital because of VT un-detection leading to a syncopal event which happened on day 144 post-implantation. 44 of readmission days directly related to ICD problems happened because of these complications, and a total of 4 patients had to be referred to another institute to deal with these complications as outlined above as our institute lacked the technology or the personnel to deal with those complications. For a summary of device complication refer to (table-5).
Discussion ICD/BVPs are very effective life-saving devices that are also very costly which is an important limitation to their use; device only cost in our registry was 425950 Australian Dollars. In addition their use can be associated with a lot of complications that can affect patients' quality of life quite adversely; these complications make the second important limitation to the expansion in their use. The incidence of ICD complications is difficult to determine due to inconsistent definitions and the lack of mandatory reporting. Information comes from annual reports filed with the United States Food and Drug Administration, by companies that make devices and from voluntary registries (2). Approximately 50% of patients experience an adverse event within the first year after ICD implantation (2, 3). The rate of freedom from any adverse event at 1, 3, and 12 months was 79, 68, and 51 percent, respectively as was illustrated in a prospective study of 778 patients receiving a trans- venous ICD (2,3) . Among the complications that occurred, 60 % were due to the ICD system, 29 % were related to the implantation procedure and 11 % were not device-related (2). As far as procedural complications are concerned, a peri-procedural mortality of 0-0.8 % has been reported (2), incidence of severe bleeding was 1.5%, and infection of the generator pocket or leads has been reported in up to 7%. ICD system problems included lead failure; the estimated lead survival rates at 5 and 8 years are 85% and 60% respectively. The annual defect rate increases with time and reaches 20% in 10-year-old leads (5) mainly due to lead dislodgement, fracture, and insulation defects (2, 5). The other common complication is inappropriate shocks which occurred in 20-25% of ICD patients the main cause being supra-ventricular tachy-arrhythmias including sinus tachycardia, atrial fibrillation, and the other important cause is non-sustained VT (2).
In conclusion, we believe that ICDs are very effective lifesaving devices but unfortunately they still are very expensive and their use can be associated with significant morbidities especially during the learning curve. We appreciate the limitation of our data and that generalisation is difficult because our sample size is quite small, and it early experience in a single public hospital with a relatively low volume of device implantation basically led by one cardiologist. But we believe that it represents the experience of many programs on a learning curve and we present our experience to help those planning to start a similar program. PEER REVIEW Not commissioned; externally peer reviewed
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